Resverlogix Provides Quarterly Update



    
    Alzheimer's disease biomarker assessment to be added to the
    Phase 1b/2a trial
    

    TSX Exchange Symbol: RVX

    CALGARY, April 28 /CNW/ - Resverlogix Corp. ("Resverlogix" or "Company")
(TSX:RVX) is pleased to provide a corporate update on activities as well as an
interim progress report for Resverlogix's lead drug, RVX-208. Currently
Resverlogix is conducting a human Phase 1b/2a clinical trial for the
assessment of RVX-208, a new class of drugs, for the treatment of
atherosclerosis. The primary endpoints for this trial are safety and
tolerability. To date, Resverlogix would also like to announce that RVX-208
has demonstrated that it is safe, tolerable and has favorable
pharmacokinetics. The study is a double blinded placebo trial, thus an interim
analysis will not be released until after the completion date of July 2009. As
a result of the recently announced financing, completion of the third arm of
the Phase 1b/2a trial has recommenced. Resverlogix is also pleased to announce
that it will be adding a new assessment of a biomarker for Alzheimer's disease
to the third and final arm of this clinical trial.
    "The unmet medical need of treating subjects with low levels of ApoA-I,
"the HDL protein", is huge. RVX-208 has received a great deal of recognition
based on current data. In parallel with advancing the clinical program for
RVX-208 we have also made distinct progress in delineating the unique
mechanism of action by which RVX-208 increases ApoA-I production," stated
Donald J. McCaffrey, President and CEO of Resverlogix. "This data will in part
be communicated by Dr. Norman Wong, MD and Chief Scientific Officer of
Resverlogix at the upcoming American Heart Association (AHA) conference,"
added McCaffrey.
    Resverlogix is also pleased to announce that it will host a live
teleconference on Thursday, April 30, 2009 at 10:00 am MDT. The purpose of the
teleconference is to provide a year-end update on both the science and the
business aspects of the Company. The dial-in numbers for this event are
international 1-604-638-5340 and toll free 1-800-319-4610. A link for this
webcast will be posted onto the homepage of Resverlogix's website and can be
accessed from the following address
http://services.choruscall.com/links/resverlogix090430.html.

    Quarterly Update Highlights

    On April 15, 2009 Resverlogix announced the closing of a US $20 million
financing which will allow the Company to continue its research and
development activities in addition to its clinical operations. As part of this
financing, terms for a second financing tranche were also negotiated for up to
an additional US $15 million that can be optionally accepted at Resverlogix's
discretion.
    "Resverlogix has accomplished several key milestones many of which have
been achieved recently. Our novel ApoA-I/HDL technology has received
international attention from esteemed leaders during the recent American
College of Cardiology (ACC) Scientific Sessions. These advances in RVX's
technology accelerated progress in our current clinical trial and was
summarized in a recent Wall Street Journal article," stated McCaffrey.
    At the most recent ACC conference held in Orlando Florida RVX-208 was the
subject of two key plenary sessions. Dr. Steven Nissen, Chairman of the
Department of Cardiovascular Medicine at the Cleveland Clinic presented
Resverlogix data. In his keynote address Dr. Nissen spoke to an audience of
over 1,500 key medical, research and industry stakeholders where he
highlighted HDL and ApoA-I as valid drug research targets for the ongoing risk
that still remains among the millions of low HDL patients worldwide. As one of
several hopeful strategies to combat the unmet medical need in
atherosclerosis, Dr. Nissen highlighted the promising early results of RVX-208
on important atherosclerosis markers such as HDL, ApoA-I and pre-beta HDL as
well as introducing the drug's novel mechanism of action. Several leaders in
the field supported the notion of huge potential for ApoA-I to treat
atherosclerosis and cardiovascular disease.
    In a second keynote address during the same ACC conference Dr. Prediman
K. Shah, Director of the Division of Cardiology and the Atherosclerosis
Research Center at Cedars-Sinai Medical Center highlighted the advances of
RVX-208 during his presentation titled "Novel strategies to increase HDL".
During his presentation, Dr. Shah reviewed the unique features of RVX-208's
novel mechanism of action and properties by which ApoA-I and functional HDL
are increased.
    Resverlogix continues to expand its scientific leadership through
participation in key scientific conferences including presenting data on April
30, 2009 during the AHA Arteriosclerosis, Thrombosis and Vascular Biology
Annual conference. On June 18, 2009 Resverlogix will be participating in a
workshop that examines therapies which enhance reverse cholesterol transport
during the XV International Symposium on Atherosclerosis hosted by the
International Atherosclerosis Society.
    Resverlogix granted 1,430,000 stock options to new employees, officers
and directors and existing employees whose options expired during an extensive
blackout period. During the past fiscal year 1,483,900 option grants expired,
of which all director and officers expired options were priced below current
market value. Given the expiry of these options, the new grant has a neutral
effect on the capital structure of the company. The stock options plan
provides for the issuance of up to a maximum of 10% of the issued and
outstanding common shares. Subsequent to this option grant, the total options
outstanding is equal to 6.9% of the issued and outstanding common shares and
was 4.7% prior to the recent financing.

    About RVX-208

    RVX-208, a novel small molecule therapeutic that facilitates endogenous
ApoA-I production, is positioned to be one of the most promising emerging
drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208
is the only novel small molecule that is specifically designed to increase
ApoA-I production and thereby raise HDL levels thus enhancing HDL
functionality to augment reverse cholesterol transport.

    About Resverlogix Corp.

    Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) PR program is the Company's primary
focus which is to develop novel small molecules that enhance ApoA-I. These
vital therapies address the grievous burden of atherosclerosis and other
important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's
disease, Peripheral Artery Disease and other vascular disorders. Resverlogix
Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information
please visit www.resverlogix.com.

    This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.

    %SEDAR: 00019253E




For further information:

For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Fax: (403) 256-8495, Email:
Theresa@resverlogix.com; Donald McCaffrey, President & CEO, Resverlogix Corp.,
Phone: (403) 254-9252, Fax: (403) 256-8495, Email: Don@resverlogix.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890